Petr Cigler1
IOCB AS CR vvi1
Lipid nanoparticles (LNPs) are the most advanced nonviral modality for nucleic acid (NA) delivery, and have recently gained enormous attention in the fields of RNA therapeutics and vaccine development. New type of ionizable adamantane-based lipidoids named XMaNs [1], which circumvent the usual need for laborious optimization of LNP components for highly diverse types of NAs, will be presented. The non-toxic XMaN6 lipidoid is highly versatile in entrapment and delivery of siRNA, mRNA, plasmid DNA, and a cyclic dinucleotide. XMaN6-based LNPs efficiently deliver: 1) siRNA into human primary hepatocytes and cell lines that are hard-to-transfect; 2) mRNA into mouse liver; 3) plasmid DNA; 4) 2′,3′-cGAMP into cells and activated the cGAS-STING pathway three orders of magnitude more efficiently than 2′,3′-cGAMP<br/>alone. Such universality in delivering different NA types is unique and can accelerate translation of LNPs into the clinic.<br/><br/>[1] <i>Adv. Funct. Mater.</i> <b>2021</b>, 2101391.